HK1042439B - 一氫苯並卟啉衍生物的乙二醇酯作為光活性試劑的用途 - Google Patents

一氫苯並卟啉衍生物的乙二醇酯作為光活性試劑的用途

Info

Publication number
HK1042439B
HK1042439B HK02104249.9A HK02104249A HK1042439B HK 1042439 B HK1042439 B HK 1042439B HK 02104249 A HK02104249 A HK 02104249A HK 1042439 B HK1042439 B HK 1042439B
Authority
HK
Hong Kong
Prior art keywords
ethylene glycol
glycol esters
photoactive agents
monohydrobenzoporphyrin
derivatives
Prior art date
Application number
HK02104249.9A
Other languages
English (en)
Inventor
Ronald E Boch
Ethan Sternberg
David Dolphin
Julia G Levy
Anna M Richter
David W C Hunt
Jain Ashok
Elizabeth M Waterfield
Andrew N Tovey
Original Assignee
Quadra Logic Tech Inc
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc, Univ British Columbia filed Critical Quadra Logic Tech Inc
Publication of HK1042439B publication Critical patent/HK1042439B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
HK02104249.9A 1997-05-07 2002-06-05 一氫苯並卟啉衍生物的乙二醇酯作為光活性試劑的用途 HK1042439B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85249497A 1997-05-07 1997-05-07

Publications (1)

Publication Number Publication Date
HK1042439B true HK1042439B (zh) 2014-02-28

Family

ID=25313492

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104249.9A HK1042439B (zh) 1997-05-07 2002-06-05 一氫苯並卟啉衍生物的乙二醇酯作為光活性試劑的用途

Country Status (21)

Country Link
US (2) US5929105A (zh)
EP (2) EP1177795B1 (zh)
JP (1) JP3378889B2 (zh)
KR (1) KR100397131B1 (zh)
CN (1) CN1113882C (zh)
AR (1) AR012673A1 (zh)
AT (1) ATE211473T1 (zh)
AU (1) AU741070B2 (zh)
CA (1) CA2284879C (zh)
CZ (1) CZ294715B6 (zh)
DE (1) DE69803376T2 (zh)
DK (1) DK0983273T3 (zh)
ES (2) ES2437790T3 (zh)
HK (1) HK1042439B (zh)
HU (1) HU221754B1 (zh)
IL (1) IL132066A (zh)
NO (1) NO314264B1 (zh)
NZ (1) NZ338031A (zh)
PL (1) PL202341B1 (zh)
PT (1) PT983273E (zh)
WO (1) WO1998050387A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
US6364907B1 (en) 1998-10-09 2002-04-02 Qlt Inc. Method to prevent xenograft transplant rejection
US6331235B1 (en) * 1998-12-11 2001-12-18 The University Of British Columbia Chiral separation of benzoporphyrin derivative mono-and di-acids by laser-induced fluorescence capillary electrophoresis
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
WO2000041726A2 (en) * 1999-01-15 2000-07-20 Light Sciences Corporation Noninvasive vascular therapy
WO2000051638A1 (en) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Photodynamic therapy in combination with apoptosis inducing factors
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6609014B1 (en) 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US20040208855A1 (en) * 1999-11-17 2004-10-21 Allison Beth Anne Use of PDT to inhibit intimal hyperplasia
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
CA2408332C (en) 2000-05-08 2011-02-15 The University Of British Columbia Supports for photosensitizer formulations
US6693093B2 (en) 2000-05-08 2004-02-17 The University Of British Columbia (Ubc) Drug delivery systems for photodynamic therapy
KR20080080685A (ko) * 2000-11-29 2008-09-04 피씨아이 바이오테크 에이에스 사이토졸 내로의 분자 전달을 위한 광화학적 내부이행
AU2210402A (en) * 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for virus-mediated molecule delivery into the cyosol
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
EP1401506A4 (en) * 2001-05-31 2005-02-16 Miravant Pharm Inc METAL TETRAPYRROLIC PHOTOSENSITIZATION AGENTS FOR PHOTODYNAMIC THERAPY
ES2320430T3 (es) * 2001-08-22 2009-05-22 Montana State University-Bozeman Porfirinas con secciones eficaces de absorcion multifotonica mejoradas para terapia fotodinamica.
DE60225844T2 (de) * 2001-11-02 2009-04-09 The Governors Of The University Of Alberta, Edmonton Micelle-zusammensetzungen enthaltend pegylierten phospholipide und einen photosensibilisator
NZ533036A (en) * 2001-11-09 2006-04-28 Quadra Logic Tech Inc Compositions comprising a photosensitizer and skin penetration enhancer and their use in photodynamic treatment for alopecia cancer acne psoriasis dermatitis ablation and promoting hair growth
US7264629B2 (en) 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
BR112012000254A2 (pt) 2009-07-08 2016-02-16 Dermira Canada Inc análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas.
EP2531206B1 (en) 2010-02-04 2017-05-31 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
KR20140089478A (ko) 2011-01-13 2014-07-15 큐엘티 인코포레이티드 감광제의 국소 전달용 약학 조성물 및 그의 이용
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
JP6181059B2 (ja) 2011-10-25 2017-08-16 メモリアル スローン−ケタリング キャンサー センター 前立腺がんのための診断薬、予後判定薬、および治療薬としてのフリーｐｓａ抗体
JP2015522079A (ja) 2012-07-11 2015-08-03 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． 光線感作物質の局所送達のための医薬組成物及びその使用
CA2889756C (en) 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
WO2015100113A2 (en) 2013-12-23 2015-07-02 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer using peptide nucleic acid-based agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
WO1990015059A1 (en) * 1989-06-07 1990-12-13 The University Of British Columbia Photosensitizing diels-alder porphyrin derivatives
US5498710A (en) * 1994-04-22 1996-03-12 Health Research, Inc. Alkyl ether analogues of benzoporphyrin derivatives
DE69819318T2 (de) * 1997-05-07 2004-08-19 The University Of British Columbia, Vancouver Ein klasse von benzoporphyrin derivate photowirksame verbindungen

Also Published As

Publication number Publication date
ES2171022T3 (es) 2002-08-16
CN1113882C (zh) 2003-07-09
IL132066A (en) 2008-06-05
AU741070B2 (en) 2001-11-22
CN1254339A (zh) 2000-05-24
EP0983273B8 (en) 2002-10-09
EP1177795A3 (en) 2002-05-29
EP1177795A2 (en) 2002-02-06
HUP0003604A3 (en) 2002-04-29
NO995436D0 (no) 1999-11-05
US5929105A (en) 1999-07-27
DE69803376D1 (de) 2002-02-28
JP3378889B2 (ja) 2003-02-17
CA2284879A1 (en) 1998-11-12
WO1998050387A1 (en) 1998-11-12
CA2284879C (en) 2005-10-25
US6153639A (en) 2000-11-28
EP1177795B1 (en) 2013-09-11
JP2001507369A (ja) 2001-06-05
KR20010012331A (ko) 2001-02-15
HU221754B1 (hu) 2002-12-28
DK0983273T3 (da) 2002-04-22
HUP0003604A2 (hu) 2001-02-28
PL202341B1 (pl) 2009-06-30
EP0983273B1 (en) 2002-01-02
PL336790A1 (en) 2000-07-17
ATE211473T1 (de) 2002-01-15
CZ392399A3 (cs) 2000-02-16
KR100397131B1 (ko) 2003-09-13
NO995436L (no) 2000-01-04
CZ294715B6 (cs) 2005-02-16
EP0983273A1 (en) 2000-03-08
ES2437790T3 (es) 2014-01-14
NZ338031A (en) 2001-04-27
AR012673A1 (es) 2000-11-08
AU7420798A (en) 1998-11-27
PT983273E (pt) 2002-06-28
NO314264B1 (no) 2003-02-24
DE69803376T2 (de) 2002-08-14
IL132066A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
HK1042439B (zh) 一氫苯並卟啉衍生物的乙二醇酯作為光活性試劑的用途
HUP0000575A3 (en) Novel formulation comprising budesonid as active indegredient
GB9403857D0 (en) Fatty acid derivatives
PL337773A1 (en) Derivatives of benzimidazoles
PL340254A1 (en) Derivatives of pleuromutillin as antimicrobial agents
NO2011015I2 (no) Paliperidon palmitatester
IL126095A0 (en) Azolobenzazepine derivatives as neurogically active agents
HU9801044D0 (en) Sulfonyl-amino-carboxylic acid derivatives
PL339660A1 (en) Derivatives of amidocarboxylic acids
HUP0000937A3 (en) New fatty acid derivatives
PL332416A1 (en) Substituted heterocyclic compounds as anticarcinogenic agents
PL336348A1 (en) Indazolamide compounds as serotoninergic agents
HUP0004071A3 (en) Pharmaceutical compositions comprising prostaglandin derivatives
EP0986378A4 (en) ANTINEOPLASTIC PHORBOLESTER
PL331151A1 (en) Analoques of illudin useful as anticarcinogenic agents
ZA957187B (en) Use of substituted 4-phenyl-6-amino-nicotinic acid derivatives as medicaments
EP0775134A4 (en) NEW BENZIMIDAZOLE DERIVATIVES
PL340461A1 (en) Derivatives of isothiazocarboxylic acid
GB9721070D0 (en) Bioactive derivatives of camptothecin
GR3031027T3 (en) Piperidineacetic acid derivatives useful as fibrinogen antagonist agent
HU9801072D0 (en) Substituted 6- and 7-amino-tetrahydro-isoquinoline-carboxylic acid derivatives
NO20003105D0 (no) Fenylaminoalkylkarboksylsyre-derivater samt medisinske sammensetninger omfattende slike
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
GB9414453D0 (en) New heterobicyclic derivatives
PL339922A1 (en) Derivatives of diphenyl as pharmacological agents

Legal Events

Date Code Title Description
ARF Application filed for restoration

Effective date: 20100506

ARG Restoration of standard patent granted

Effective date: 20100719

CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: TOVEY, ANDREW N. - 351/354

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170506